[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Powers Medical Devices, LLC\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":135},{"warningLetters":4,"total":134},[5,31,51,74,94,116],{"id":6,"raw":7,"subject":14,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":20,"body_fetched_at":28,"delivery_method":29,"recipient_title":20,"reference_number":20,"action_taken_date":30,"medical_device_id":20,"response_letter_date":20},3703,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2026-06-16T04:00:00Z\">06\u002F16\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-06-08T04:00:00Z\">06\u002F08\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdh-medical-services-728238-06082026\">D&amp;H Medical Services\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","False &amp; Misleading Claims\u002FMisbranded (Telehealth)","","False & Misleading Claims\u002FMisbranded (Telehealth)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>D&amp;H Medical Services\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2500 NW 79th Avenue, Suite 265\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Doral\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33122\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@dhmedicalcenter.com\"> info@dhmedicalcenter.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 8, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference number: MARCS-CMS 728238\u003C\u002Fp>\u003Cp>To D&amp;H Medical Services:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were identified and documented during a review of D&amp;H Medical Services’ website, https:\u002F\u002Fwww.dhmedicalcenter.com, FDA Establishment Identifier (FEI) 3044174854, in March 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)]. This review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor quality drug products.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\u003C\u002Fp>\u003Cp>Your representations regarding compounded semaglutide and tirzepatide products are false or misleading. Under section 502(a) of the FD&amp;C Act [21 U.S.C. § 352(a)], a drug product is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FD&amp;C Act [21 U.S.C. § 352(bb)], a compounded drug product is misbranded if its advertising or promotion is false or misleading in any particular.\u003C\u002Fp>\u003Cp>More specifically,\u003C\u002Fp>\u003Cp>1. The following claims concerning compounded semaglutide and tirzepatide products appear on your website:\u003C\u002Fp>\u003Cul>\u003Cli>“Same ingredient as Ozempic®”\u003C\u002Fli>\u003Cli>“Same ingredient as Rybelsus®”\u003C\u002Fli>\u003Cli>“Same ingredient as Mounjaro®”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Compounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.\u003C\u002Fp>\u003Cp>Accordingly, these representations cause your compounded drug products to be misbranded under sections 502(a) and 502(bb) of the FD&amp;C Act [21 U.S.C. §§ 352(a) and (bb)]. The introduction or delivery for introduction into interstate commerce of these misbranded drug products is a prohibited act under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)]. The violations described in this letter put you on notice of our concerns but may not represent an exhaustive list of violations. Please be advised, the receipt in interstate commerce of misbranded drug products, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FD&amp;C Act [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>You are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&amp;C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the FD&amp;C Act, including the new drug approval requirements.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>Send your written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance at compoundinginspections@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with reference number MARCS-CMS 728238 and Response to Warning Letter in the subject line of the email. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Such steps may include the following:\u003C\u002Fp>\u003Cp>1. Identifying the entities that produce the compounded drug products offered on your website;\u003C\u002Fp>\u003Cp>2. Providing a representative sample of labeling for such drug products; and\u003C\u002Fp>\u003Cp>3. Addressing other website claims that contain false or misleading representations about your compounded drug products or demonstrating that such claims have been modified or removed in light of FD&amp;C Act §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a) and 352(bb)].\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration. If you cannot completely address this matter within fifteen (15) business days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that drug products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your drug products referenced above appear to be misbranded drug products that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>Please note FDA posts warning letters on www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew J. Lash, JD\u003Cbr>Acting Director\u003Cbr>Office of Compounding Quality and Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>________________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FD&amp;C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FD&amp;C Act [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nD&H Medical Services\n\n2500 NW 79th Avenue, Suite 265\n\nDoral, FL 33122\n\nUnited States\n\ninfo@dhmedicalcenter.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nJune 8, 2026\nWARNING LETTER\nReference number: MARCS-CMS 728238\nTo D&H Medical Services:\nThis warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nFDA Review\nViolations were identified and documented during a review of D&H Medical Services’ website, https:\u002F\u002Fwww.dhmedicalcenter.com, FDA Establishment Identifier (FEI) 3044174854, in March 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.1 As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]. This review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor quality drug products.\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\nYour representations regarding compounded semaglutide and tirzepatide products are false or misleading. Under section 502(a) of the FD&C Act [21 U.S.C. § 352(a)], a drug product is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FD&C Act [21 U.S.C. § 352(bb)], a compounded drug product is misbranded if its advertising or promotion is false or misleading in any particular.\nMore specifically,\n1. The following claims concerning compounded semaglutide and tirzepatide products appear on your website:\n“Same ingredient as Ozempic®”\n“Same ingredient as Rybelsus®”\n“Same ingredient as Mounjaro®”\nCompounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.\nAccordingly, these representations cause your compounded drug products to be misbranded under sections 502(a) and 502(bb) of the FD&C Act [21 U.S.C. §§ 352(a) and (bb)]. The introduction or delivery for introduction into interstate commerce of these misbranded drug products is a prohibited act under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]. The violations described in this letter put you on notice of our concerns but may not represent an exhaustive list of violations. Please be advised, the receipt in interstate commerce of misbranded drug products, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FD&C Act [21 U.S.C. § 331(c)].\nYou are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the FD&C Act, including the new drug approval requirements.\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nSend your written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance at compoundinginspections@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with reference number MARCS-CMS 728238 and Response to Warning Letter in the subject line of the email. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Such steps may include the following:\n1. Identifying the entities that produce the compounded drug products offered on your website;\n2. Providing a representative sample of labeling for such drug products; and\n3. Addressing other website claims that contain false or misleading representations about your compounded drug products or demonstrating that such claims have been modified or removed in light of FD&C Act §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a) and 352(bb)].\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration. If you cannot completely address this matter within fifteen (15) business days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that drug products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your drug products referenced above appear to be misbranded drug products that cannot be legally sold to consumers in the U.S.\nPlease note FDA posts warning letters on www.FDA.gov.\nSincerely,\n\u002FS\u002F\nMatthew J. Lash, JD\nActing Director\nOffice of Compounding Quality and Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n________________________________\n1 The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FD&C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FD&C Act [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.","D&H Medical Services","dh-medical-services-728238-06082026","2026-08-19T04:06:48.349905+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdh-medical-services-728238-06082026","2026-10-26T08:08:24.115003+00:00","Warning Letter","Issued","2026-06-16","728238","Drugs","2026-08-19T04:34:50.914+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","2026-06-08",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":20,"letter_url":44,"updated_at":45,"action_type":23,"case_status":24,"posted_date":46,"marcs_cms_no":47,"product_type":27,"closeout_date":20,"issuing_office":37,"recipient_name":48,"body_fetched_at":49,"delivery_method":20,"recipient_title":20,"reference_number":20,"action_taken_date":50,"medical_device_id":20,"response_letter_date":20},2257,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2023-01-11T15:00:00Z\">01\u002F11\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-01-10T05:00:00Z\">01\u002F10\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedical-mikes-inc-647603-01102023\">Medical Mikes, Inc.\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mike Vanacoro\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Medical Mikes, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3393 Nutly Circle\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Yorktown Heights\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>10598\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:hello@medicalmikes.com\"> hello@medicalmikes.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n         \n          \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan> Federal Trade Commission\u003C\u002Fdd>\n\n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>RE: 647603\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: January 10, 2023\u003C\u002Fp>\n\n\u003Cp>RE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your website at the Internet address https:\u002F\u002Fmedicalmikes.com\u002F on December 7, 2022, and January 6, 2023, respectively. The FDA has observed that your website offers cannabidiol (CBD) products for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&amp;C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&amp;C Act, 21 U.S.C. § 331(a) and (d)\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>Some examples of the claims on your website that establish the intended use of your products and misleadingly represent them as safe and\u002For effective for the treatment or prevention of COVID-19 include:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Health Benefits of CBD Oil\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The science behind CBD and health continues to grow every day, and emerging studies have linked CBD to a number of medicinal and health benefits. The application of CBD is broad and can help alleviate symptoms of many common ailments. . . .\u003C\u002Fp>\n\n\u003Cp>&nbsp; o Boosts Immune System: This 2020 review of existing research concluded that CBD could control immune responses to cytokines, chemokines, and regulatory cell induction, creating a potential use case for Covid treatment by preventing Cytokine Storms–the condition that transforms standard cases into life-threatening scenarios.” [From your September 2021 blog post titled “CBD FOR SENIORS: BEST PRODUCTS, BENEFITS, SAFETY, AND USES” https:\u002F\u002Fmedicalmikes.com\u002Fblogs\u002Fmedical-mikes-blog\u002Fcbd-for-seniors-best-products-benefits-safety-and-uses]\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Researchers Recommend CBD-Based Clinical Trials for Covid-19 Prevention\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Marsha Rosner of the University of Chicago and her team, who recently published a study in Science Advances, want to see CBD at the forefront of Covid-19 prevention studies. Why? Their widely circulated research indicated that highly potent oral CBD inhibits Covid infection in human lung cells and mice. According to their findings, CBD may work by inhibiting viral gene expression while boosting the body’s stress and immune responses.” [From your February 2022 blog post titled “COVID-19 AND CBD RESEARCH: THE LATEST FINDINGS AND TAKEAWAYS” https:\u002F\u002Fmedicalmikes.com\u002Fblogs\u002Fmedical-mikes-blog\u002Fcovid-19-and-cbd-research-the-latest-findings-and-takeaways]\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Lab Research Says CBDa and CBGa Can Stop Covid-19\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We’ve talked a lot about the potential of concentrated, oral CBD formulas for Covid-19. But what about other hemp compounds? . . .\u003C\u002Fp>\n\n\u003Cp>Study investigators found that, of hemp’s hundreds of cannabinoids, CBDa and CBGa exhibited the most powerful ability to inhibit the Covid protein from seizing human cells. Even more profound, these minor cannabinoids reduced viral infection loads (still, in a petri dish) by an astounding 50%.” [From your February 2022 blog post titled “COVID-19 AND CBD RESEARCH: THE LATEST FINDINGS AND TAKEAWAYS” https:\u002F\u002Fmedicalmikes.com\u002Fblogs\u002Fmedical-mikes-blog\u002Fcovid-19-and-cbd-research-the-latest-findings-and-takeaways]\u003C\u002Fp>\n\n\u003Cp>You should take immediate action to address this matter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&amp;C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&amp;C Act.\u003Cstrong> Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&amp;C Act. This list can be found at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products\">http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>FTC Cease and Desist Demand:\u003C\u002Fstrong> In addition, it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the products identified above. Thus, any coronavirus-related prevention or treatment claims regarding such products are not supported by competent and reliable scientific evidence. You must immediately cease and desist making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $50,120 per violation and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). Within 48 hours, please send an email to Serena Viswanathan, Associate Director of the FTC’s Division of Advertising Practices, at sviswanathan@ftc.gov certifying that you have ceased making unsubstantiated claims for the product identified above. If you have any questions regarding compliance with the FTC Act, please contact Ms. Viswanathan at 202-326-3244.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CAPT Tina Smith\u003Cbr>\nActing Director\u003Cbr>\nOffice of Unapproved Drugs and Labeling Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>Sincerely,&nbsp;\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Serena Viswanathan\u003Cbr>\nAssociate Director\u003Cbr>\nDivision of Advertising Practices\u003Cbr>\nFederal Trade Commission\u003C\u002Fp>\n\n\u003Cp>______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMike Vanacoro\n\nMedical Mikes, Inc.\n\n3393 Nutly Circle\n\nYorktown Heights, NY 10598\n\nUnited States\n\nhello@medicalmikes.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nFederal Trade Commission\n\nWARNING LETTER\n\nRE: 647603\n\nDate: January 10, 2023\n\nRE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your website at the Internet address https:\u002F\u002Fmedicalmikes.com\u002F on December 7, 2022, and January 6, 2023, respectively. The FDA has observed that your website offers cannabidiol (CBD) products for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-191 in people. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nSome examples of the claims on your website that establish the intended use of your products and misleadingly represent them as safe and\u002For effective for the treatment or prevention of COVID-19 include:\n\n“Health Benefits of CBD Oil\n\nThe science behind CBD and health continues to grow every day, and emerging studies have linked CBD to a number of medicinal and health benefits. The application of CBD is broad and can help alleviate symptoms of many common ailments. . . .\n\no Boosts Immune System: This 2020 review of existing research concluded that CBD could control immune responses to cytokines, chemokines, and regulatory cell induction, creating a potential use case for Covid treatment by preventing Cytokine Storms–the condition that transforms standard cases into life-threatening scenarios.” [From your September 2021 blog post titled “CBD FOR SENIORS: BEST PRODUCTS, BENEFITS, SAFETY, AND USES” https:\u002F\u002Fmedicalmikes.com\u002Fblogs\u002Fmedical-mikes-blog\u002Fcbd-for-seniors-best-products-benefits-safety-and-uses]\n\n“Researchers Recommend CBD-Based Clinical Trials for Covid-19 Prevention\n\nMarsha Rosner of the University of Chicago and her team, who recently published a study in Science Advances, want to see CBD at the forefront of Covid-19 prevention studies. Why? Their widely circulated research indicated that highly potent oral CBD inhibits Covid infection in human lung cells and mice. According to their findings, CBD may work by inhibiting viral gene expression while boosting the body’s stress and immune responses.” [From your February 2022 blog post titled “COVID-19 AND CBD RESEARCH: THE LATEST FINDINGS AND TAKEAWAYS” https:\u002F\u002Fmedicalmikes.com\u002Fblogs\u002Fmedical-mikes-blog\u002Fcovid-19-and-cbd-research-the-latest-findings-and-takeaways]\n\n“Lab Research Says CBDa and CBGa Can Stop Covid-19\n\nWe’ve talked a lot about the potential of concentrated, oral CBD formulas for Covid-19. But what about other hemp compounds? . . .\n\nStudy investigators found that, of hemp’s hundreds of cannabinoids, CBDa and CBGa exhibited the most powerful ability to inhibit the Covid protein from seizing human cells. Even more profound, these minor cannabinoids reduced viral infection loads (still, in a petri dish) by an astounding 50%.” [From your February 2022 blog post titled “COVID-19 AND CBD RESEARCH: THE LATEST FINDINGS AND TAKEAWAYS” https:\u002F\u002Fmedicalmikes.com\u002Fblogs\u002Fmedical-mikes-blog\u002Fcovid-19-and-cbd-research-the-latest-findings-and-takeaways]\n\nYou should take immediate action to address this matter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&C Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&C Act. This list can be found at http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products. Once you have taken actions to address the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nIf you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov.\n\nFTC Cease and Desist Demand: In addition, it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the products identified above. Thus, any coronavirus-related prevention or treatment claims regarding such products are not supported by competent and reliable scientific evidence. You must immediately cease and desist making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $50,120 per violation and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). Within 48 hours, please send an email to Serena Viswanathan, Associate Director of the FTC’s Division of Advertising Practices, at sviswanathan@ftc.gov certifying that you have ceased making unsubstantiated claims for the product identified above. If you have any questions regarding compliance with the FTC Act, please contact Ms. Viswanathan at 202-326-3244.\n\nSincerely,\n\n\u002FS\u002F\n\nCAPT Tina Smith\n\nActing Director\n\nOffice of Unapproved Drugs and Labeling Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\nSincerely,\n\n\u002FS\u002F\n\nSerena Viswanathan\n\nAssociate Director\n\nDivision of Advertising Practices\n\nFederal Trade Commission\n\n______________________\n\n1 As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n3 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.","Medical Mikes, Inc.","medical-mikes-inc-647603-01102023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedical-mikes-inc-647603-01102023","2026-10-26T08:09:23.002096+00:00","2023-01-11","647603","Mike Vanacoro","2026-08-20T01:19:26.495+00:00","2023-01-10",{"id":52,"raw":53,"subject":58,"body_html":59,"body_text":60,"firm_name":61,"letter_id":62,"created_at":63,"fei_number":20,"letter_url":64,"updated_at":65,"action_type":23,"case_status":24,"posted_date":66,"marcs_cms_no":67,"product_type":68,"closeout_date":20,"issuing_office":57,"recipient_name":69,"body_fetched_at":70,"delivery_method":71,"recipient_title":20,"reference_number":72,"action_taken_date":73,"medical_device_id":20,"response_letter_date":20},543,[54,55,56,57,58,13,13,13],"\u003Ctime datetime=\"2025-10-07T04:00:00Z\">10\u002F07\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-24T04:00:00Z\">09\u002F24\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnew-life-medical-services-llc-711102-09242025\">New Life Medical Services, LLC\u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","CGMP\u002FDeviations\u002FBiologics License Application (BLA)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 25-711102\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Joshua M. Mansavage\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>New Life Medical Services, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>244 Crystal Grove Blvd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Lutz\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33548-6460\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Joshm@newliferegen.com\"> Joshm@newliferegen.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>September 24, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>CBER 25- 711102\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear Mr. Mansavage:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your facility, located at the above address, between May 14, 2024, and May 20, 2024. During the inspection, FDA documented that your company sells human products derived from umbilical cord (Restor+\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>, Regain, and Renyte), an amniotic fluid derived product (ReCyte\u002FCytosomes\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>), and an exosome product (also referred to as an “extracellular vesicle” product, named Rexo) for allogeneic use (collectively, “your products”).\u003C\u002Fp>\u003Cp>This letter is to advise you that your products are unapproved new drugs in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. §355(a). Your products are also unlicensed biological products in violation of section351(a)(1) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a)(1). A biological product for which a biologics license application (BLA) has been approved undersection 351(a) of the PHS Act is not required to have an approved application undersection 505 of the FD&amp;C Act, 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act. Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. § 331(d).\u003C\u002Fp>\u003Cp>Based on information and records reviewed by FDA, including your website, www.newliferegen.com, (last visited September 2025) and your Instagram page (newliferegen, last visited September 2025), your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example:\u003C\u002Fp>\u003Cul>\u003Cli>Your website states that “Restor+ facilitates healing by secreting powerful bioactive molecules, creating an optimal environment for tissue repair and regeneration.”\u003C\u002Fli>\u003Cli>Your Physician Guide states Restor+ “has a strong anti-inflammatory effect reducing the expression of inflammatory cytokines.”\u003C\u002Fli>\u003Cli>Your training videos demonstrate use of Restor+, occasionally in conjunction with Rexo, in the treatment of several conditions, including neuropathy and bone spurs, as well as treating pain and inflammation.\u003C\u002Fli>\u003Cli>Your package insert for Regain states it is intended “to supplement the recipient’s tissue and assist in the body’s natural regenerative functions.”\u003C\u002Fli>\u003Cli>Your Physician Guide states:\u003Cbr>o “Higher concentration of growth factors in Renyte act as anti-inflammatory and have been shown to prevent cell death.”\u003Cbr>o Renyte is intended to “supplement or replace damaged or inadequate connective tissue.”\u003C\u002Fli>\u003Cli>Your product update for Cytosomes to ReCyte indicates that “Recyte is intended to help with inflammation and to enhance the healing process.”\u003C\u002Fli>\u003Cli>Your website states that “Rexo is an innovative extracellular vesicle product derived from Wharton’s Jelly that offers advanced healing properties.”\u003C\u002Fli>\u003Cli>One of your Instagram posts states, “Flagship Products … Restor+ and Rexo … Ideal Applications” and lists orthopedic procedures, paraspinal treatments, hair restoration therapies, and neuropathy interventions.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In addition, evidence obtained during the inspection documents your representation that, “[New Life Medical Services] products across the board are utilized for pain management, inflammation of soft tissue, … and non-union fractures. ‘The application for all products are copy, paste.’”\u003C\u002Fp>\u003Cp>Therefore, your products are drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\u003C\u002Fp>\u003Cp>Your Restor+, Regain, and Renyte products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, New Life Medical Services does not qualify for any exception in 21 CFR 1271.15, and Restor+, Regain, and Renyte fail to meet all criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\u003Cp>For example, your Restor+, Regain, and Renyte products fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because the processing alters the original relevant characteristics of the umbilical cord tissue related to its utility for reconstruction, repair, or replacement. The processing of the umbilical cord from the form of a conduit into an injectable form, significantly alters the physical state of the HCT\u002FP. The umbilical cord is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form.\u003C\u002Fp>\u003Cp>In addition, your Restor+, Regain, and Renyte products fail to meet the criterion that the HCT\u002FPs be “intended for homologous use only,” which means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor” (21 CFR 1271.3(c) and 1271.10(a)(2)). Your product is not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit for umbilical cord). Rather, your products are intended for use in healing\u002Fsupplementing tissue, orthopedic procedures, treating neuropathy, and reduction of inflammation which are not basic functions of umbilical cord in the donor.\u003C\u002Fp>\u003Cp>Therefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your Restor+, Regain, and Renyte products are regulated as drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\u003C\u002Fp>\u003Cp>Subject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\u003C\u002Fp>\u003Cp>\u003Cstrong>Additional Concerns\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition to the violations described above, we have concerns about the following products:\u003C\u002Fp>\u003Cul>\u003Cli>FDA’s review of your website and other records found that you market additional products, an umbilical cord derived product named Restor Charge and an exosome-based product named Rexo Charge\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. Based on our review, these products are drugs and\u002For biological products, which are subject to premarket review and approval requirements. In your response, please provide a customer list for each of these products and indicate whether you believe you sell them in compliance with the FD&amp;C Act. If so, include your explanation why; if not, include your plan for coming into compliance.\u003C\u002Fli>\u003Cli>We also direct your attention to FDA’s Public Safety Notification on Exosome Products, available at https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fsafety-availability-biologics\u002Fpublic-safety-notification-exosome-products. FDA issued this public safety notification following multiple reports of serious adverse events experienced by patients who were treated with exosome products.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>Please submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Melissa J. Mendoza\u003Cbr>Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>__________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Restor+ is also referred to as restor+, restor, Restor, Restor Plus Wharton’s Jelly, and Restor+ Wharton’s Jelly.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> You explained during the inspection that the product Cytosomes was renamed Recyte in 2023 and provided a “Product Update” that states “Cytosomes gets a new name recyte®[.] New name, same quality product.”\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Because Restor+, Regain, and Renyte fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Your Instagram post from December 19, 2024, states that “Restor Charge and Rexo Charge provide strong healing potential at a lower price, making regenerative treatments accessible for everyone.”\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nCBER 25-711102\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nJoshua M. Mansavage\n\nRecipient Title\n\nChief Executive Officer\n\nNew Life Medical Services, LLC\n\n244 Crystal Grove Blvd\n\nLutz, FL 33548-6460\n\nUnited States\n\nJoshm@newliferegen.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\nSeptember 24, 2025\nCBER 25- 711102\nDear Mr. Mansavage:\nThe United States Food and Drug Administration (FDA) inspected your facility, located at the above address, between May 14, 2024, and May 20, 2024. During the inspection, FDA documented that your company sells human products derived from umbilical cord (Restor+1, Regain, and Renyte), an amniotic fluid derived product (ReCyte\u002FCytosomes2), and an exosome product (also referred to as an “extracellular vesicle” product, named Rexo) for allogeneic use (collectively, “your products”).\nThis letter is to advise you that your products are unapproved new drugs in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. §355(a). Your products are also unlicensed biological products in violation of section351(a)(1) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a)(1). A biological product for which a biologics license application (BLA) has been approved undersection 351(a) of the PHS Act is not required to have an approved application undersection 505 of the FD&C Act, 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act. Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. § 331(d).\nBased on information and records reviewed by FDA, including your website, www.newliferegen.com, (last visited September 2025) and your Instagram page (newliferegen, last visited September 2025), your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example:\nYour website states that “Restor+ facilitates healing by secreting powerful bioactive molecules, creating an optimal environment for tissue repair and regeneration.”\nYour Physician Guide states Restor+ “has a strong anti-inflammatory effect reducing the expression of inflammatory cytokines.”\nYour training videos demonstrate use of Restor+, occasionally in conjunction with Rexo, in the treatment of several conditions, including neuropathy and bone spurs, as well as treating pain and inflammation.\nYour package insert for Regain states it is intended “to supplement the recipient’s tissue and assist in the body’s natural regenerative functions.”\nYour Physician Guide states:\no “Higher concentration of growth factors in Renyte act as anti-inflammatory and have been shown to prevent cell death.”\no Renyte is intended to “supplement or replace damaged or inadequate connective tissue.”\nYour product update for Cytosomes to ReCyte indicates that “Recyte is intended to help with inflammation and to enhance the healing process.”\nYour website states that “Rexo is an innovative extracellular vesicle product derived from Wharton’s Jelly that offers advanced healing properties.”\nOne of your Instagram posts states, “Flagship Products … Restor+ and Rexo … Ideal Applications” and lists orthopedic procedures, paraspinal treatments, hair restoration therapies, and neuropathy interventions.\nIn addition, evidence obtained during the inspection documents your representation that, “[New Life Medical Services] products across the board are utilized for pain management, inflammation of soft tissue, … and non-union fractures. ‘The application for all products are copy, paste.’”\nTherefore, your products are drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\nYour Restor+, Regain, and Renyte products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, New Life Medical Services does not qualify for any exception in 21 CFR 1271.15, and Restor+, Regain, and Renyte fail to meet all criteria in 21 CFR 1271.10(a).\nFor example, your Restor+, Regain, and Renyte products fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because the processing alters the original relevant characteristics of the umbilical cord tissue related to its utility for reconstruction, repair, or replacement. The processing of the umbilical cord from the form of a conduit into an injectable form, significantly alters the physical state of the HCT\u002FP. The umbilical cord is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form.\nIn addition, your Restor+, Regain, and Renyte products fail to meet the criterion that the HCT\u002FPs be “intended for homologous use only,” which means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor” (21 CFR 1271.3(c) and 1271.10(a)(2)). Your product is not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit for umbilical cord). Rather, your products are intended for use in healing\u002Fsupplementing tissue, orthopedic procedures, treating neuropathy, and reduction of inflammation which are not basic functions of umbilical cord in the donor.\nTherefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.3 See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your Restor+, Regain, and Renyte products are regulated as drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\nSubject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\nAdditional Concerns\nIn addition to the violations described above, we have concerns about the following products:\nFDA’s review of your website and other records found that you market additional products, an umbilical cord derived product named Restor Charge and an exosome-based product named Rexo Charge4. Based on our review, these products are drugs and\u002For biological products, which are subject to premarket review and approval requirements. In your response, please provide a customer list for each of these products and indicate whether you believe you sell them in compliance with the FD&C Act. If so, include your explanation why; if not, include your plan for coming into compliance.\nWe also direct your attention to FDA’s Public Safety Notification on Exosome Products, available at https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fsafety-availability-biologics\u002Fpublic-safety-notification-exosome-products. FDA issued this public safety notification following multiple reports of serious adverse events experienced by patients who were treated with exosome products.\nConclusion\nThis letter is not intended to be an all-inclusive list of deficiencies that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&C Act, PHS Act, and all applicable regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\nPlease submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\nSend your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at CBERDCMRecommendations@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMelissa J. Mendoza\nDirector\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\n__________________________\n1 Restor+ is also referred to as restor+, restor, Restor, Restor Plus Wharton’s Jelly, and Restor+ Wharton’s Jelly.\n2 You explained during the inspection that the product Cytosomes was renamed Recyte in 2023 and provided a “Product Update” that states “Cytosomes gets a new name recyte®[.] New name, same quality product.”\n3 Because Restor+, Regain, and Renyte fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).\n4 Your Instagram post from December 19, 2024, states that “Restor Charge and Rexo Charge provide strong healing potential at a lower price, making regenerative treatments accessible for everyone.”","New Life Medical Services, LLC","new-life-medical-services-llc-711102-09242025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnew-life-medical-services-llc-711102-09242025","2026-10-26T08:09:32.410522+00:00","2025-10-07","711102","Biologics","Joshua M. Mansavage","2026-08-19T16:15:04.082+00:00","VIA UPS and Electronic Mail","CBER 25-711102","2025-09-24",{"id":75,"raw":76,"subject":80,"body_html":81,"body_text":82,"firm_name":83,"letter_id":84,"created_at":85,"fei_number":20,"letter_url":86,"updated_at":87,"action_type":23,"case_status":24,"posted_date":88,"marcs_cms_no":89,"product_type":68,"closeout_date":20,"issuing_office":57,"recipient_name":90,"body_fetched_at":91,"delivery_method":71,"recipient_title":20,"reference_number":92,"action_taken_date":93,"medical_device_id":20,"response_letter_date":20},21927,[77,78,79,57,80,13,13,13],"\u003Ctime datetime=\"2026-10-20T04:00:00Z\">10\u002F20\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-10-06T04:00:00Z\">10\u002F06\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftides-medical-llc-727246-10062026\">Tides Medical LLC\u003C\u002Fa>","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 26-727246\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Joe Spell\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Tides Medical LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>605 Kaliste Saloom Road, Suite 1\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Lafayette\u003C\u002Fspan>, \u003Cspan>LA\u003C\u002Fspan> \u003Cspan>70508\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:jspell@tidesmedical.com\"> jspell@tidesmedical.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>October 6, 2026\u003C\u002Fp>\u003Cp>CBER 26-727246\u003C\u002Fp>\u003Cp>Dear Mr. Spell:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) has learned that your firm is distributing APLICOR 3D in the United States without marketing clearance or approval, in violation of the Federal Food, Drug, and Cosmetic Act (the Act). Under section 201(h) of the Act, 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>FDA has reviewed information and records, including your website at https:\u002F\u002Fwww.tidesmedical.com\u002Faplicor-3d\u002F (last visited October 2026), and determined that APLICOR 3D is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) for these devices in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). APLICOR 3D is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not timely notify the agency of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of these devices, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\u003C\u002Fp>\u003Cp>Your firm has stated that the APLICOR 3D device is a Class I device exempt from the requirement of premarket notification. You have indicated that the APLICOR 3D device is a liquid medication dispenser under product code KYX and 21 CFR 880.6430. Devices classified under 21 CFR 880.6430, liquid medication dispenser, are exempt from premarket notification unless they exceed the limitations of exemptions at 21 CFR 880.9. However, there is evidence that APLICOR 3D is intended for uses that are different from those of legally marketed devices classified under 21 CFR 880.6430, liquid medication dispenser. 21 CFR 880.6430(a) states that a liquid medication dispenser is a device intended for medical purposes that is used to issue a measured amount of liquid medication. However, your firm is distributing APLICOR 3D for the following intended uses:\u003C\u002Fp>\u003Cul>\u003Cli>“APLICOR 3D is a hyper-personalized 3D bioprinting platform that uses a patient’s own adipose tissue to create customized grafts for acute and chronic wounds. With a single application, this system simplifies workflows and accelerates wound progression.”\u003C\u002Fli>\u003Cli>“APLICOR 3D is a single-use 3D bioprinting system that transforms autologous adipose tissue into a personalized graft, precisely matching the size and depth of a patient’s wound.”\u003C\u002Fli>\u003Cli>“APLICOR 3D is designed for use in treating acute and chronic wounds such as diabetic foot ulcers, venous stasis ulcers, pressure injuries, burns, and trauma.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Because there is evidence that APLICOR 3D is intended for uses that are different from those of legally marketed devices classified under 21 CFR 880.6430, it exceeds the limitations described in 21 CFR 880.9 and is not exempt from premarket notification.\u003C\u002Fp>\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before FDA. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. FDA will evaluate the information that your firm submits and decide whether the products may be legally marketed.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our office requests that Tides Medical LLC cease any activities that result in the misbranding or adulteration of APLICOR 3D, including the commercial distribution of these devices for the uses discussed above.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to promptly and adequately address this matter may result in regulatory action being initiated by FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Please notify our office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions your firm has taken, which should address any systemic problems. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen (15) business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that APLICOR 3D is not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Send your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov. Refer to the CBER number at the top of this letter when replying.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm. It is your firm’s responsibility to ensure compliance with the applicable laws and regulations administered by FDA.\u003C\u002Fp>\u003Cp>Sincerely,\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Vincent Amatrudo\u003Cbr>Acting Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>___________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> FDA acknowledges receipt of your February 26, 2026, correspondence responding to the February 25, 2026, letter sent to your firm from FDA’s Center for Devices and Radiological Health.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nCBER 26-727246\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nJoe Spell\n\nRecipient Title\n\nChief Executive Officer\n\nTides Medical LLC\n\n605 Kaliste Saloom Road, Suite 1\n\nLafayette, LA 70508\n\nUnited States\n\njspell@tidesmedical.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\nOctober 6, 2026\nCBER 26-727246\nDear Mr. Spell:\nThe United States Food and Drug Administration (FDA) has learned that your firm is distributing APLICOR 3D in the United States without marketing clearance or approval, in violation of the Federal Food, Drug, and Cosmetic Act (the Act). Under section 201(h) of the Act, 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.1\nFDA has reviewed information and records, including your website at https:\u002F\u002Fwww.tidesmedical.com\u002Faplicor-3d\u002F (last visited October 2026), and determined that APLICOR 3D is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) for these devices in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). APLICOR 3D is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not timely notify the agency of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of these devices, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\nYour firm has stated that the APLICOR 3D device is a Class I device exempt from the requirement of premarket notification. You have indicated that the APLICOR 3D device is a liquid medication dispenser under product code KYX and 21 CFR 880.6430. Devices classified under 21 CFR 880.6430, liquid medication dispenser, are exempt from premarket notification unless they exceed the limitations of exemptions at 21 CFR 880.9. However, there is evidence that APLICOR 3D is intended for uses that are different from those of legally marketed devices classified under 21 CFR 880.6430, liquid medication dispenser. 21 CFR 880.6430(a) states that a liquid medication dispenser is a device intended for medical purposes that is used to issue a measured amount of liquid medication. However, your firm is distributing APLICOR 3D for the following intended uses:\n“APLICOR 3D is a hyper-personalized 3D bioprinting platform that uses a patient’s own adipose tissue to create customized grafts for acute and chronic wounds. With a single application, this system simplifies workflows and accelerates wound progression.”\n“APLICOR 3D is a single-use 3D bioprinting system that transforms autologous adipose tissue into a personalized graft, precisely matching the size and depth of a patient’s wound.”\n“APLICOR 3D is designed for use in treating acute and chronic wounds such as diabetic foot ulcers, venous stasis ulcers, pressure injuries, burns, and trauma.”\nBecause there is evidence that APLICOR 3D is intended for uses that are different from those of legally marketed devices classified under 21 CFR 880.6430, it exceeds the limitations described in 21 CFR 880.9 and is not exempt from premarket notification.\nFor a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before FDA. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. FDA will evaluate the information that your firm submits and decide whether the products may be legally marketed.\nConclusion\nOur office requests that Tides Medical LLC cease any activities that result in the misbranding or adulteration of APLICOR 3D, including the commercial distribution of these devices for the uses discussed above.\nYour firm should take prompt action to address any violations identified in this letter. Failure to promptly and adequately address this matter may result in regulatory action being initiated by FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nPlease notify our office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions your firm has taken, which should address any systemic problems. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen (15) business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that APLICOR 3D is not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\nSend your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov. Refer to the CBER number at the top of this letter when replying.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm. It is your firm’s responsibility to ensure compliance with the applicable laws and regulations administered by FDA.\nSincerely,\n\u002FS\u002F\nVincent Amatrudo\nActing Director\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\n___________________\n1 FDA acknowledges receipt of your February 26, 2026, correspondence responding to the February 25, 2026, letter sent to your firm from FDA’s Center for Devices and Radiological Health.","Tides Medical LLC","tides-medical-llc-727246-10062026","2026-10-27T01:18:54.544251+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftides-medical-llc-727246-10062026","2026-11-17T01:02:03.701861+00:00","2026-10-20","727246","Joe Spell","2026-10-27T01:19:42.766+00:00","CBER 26-727246","2026-10-06",{"id":95,"raw":96,"subject":101,"body_html":102,"body_text":103,"firm_name":104,"letter_id":105,"created_at":106,"fei_number":20,"letter_url":107,"updated_at":108,"action_type":23,"case_status":24,"posted_date":109,"marcs_cms_no":110,"product_type":111,"closeout_date":20,"issuing_office":100,"recipient_name":112,"body_fetched_at":113,"delivery_method":114,"recipient_title":20,"reference_number":20,"action_taken_date":115,"medical_device_id":20,"response_letter_date":20},350,[97,98,99,100,101,13,13,13],"\u003Ctime datetime=\"2026-02-03T05:00:00Z\">02\u002F03\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-01-08T05:00:00Z\">01\u002F08\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Funomedical-device-sa-de-cv-719428-01082026\">Unomedical Device S.A. de C.V. \u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Daihanna Peña\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Senior Director, Plant Operations\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Unomedical Device S.A. de C.V. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Parque Ind. Del Norte., Ave.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Formento Ind. Lote 9, Sec. 3\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Reynosa\u003C\u002Fspan>, \u003Cspan>Tamps.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mexico\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)@convatec.com\"> (b)(6)@convatec.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS #719428\u003C\u002Fp>\u003Cp>January 8, 2026\u003C\u002Fp>\u003Cp>Dear Ms. Peña:\u003C\u002Fp>\u003Cp>During a Remote Regulatory Assessment of your firm located in Reynosa, Tamaulipas, Mexico from July 23, 2025 through August 8, 2025, an investigator from the United States Food and Drug Administration (FDA), reviewed the records you submitted in response to our May 22 and June 6, 2025, requests for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility, determined that your firm manufactures insulin infusion sets for subcutaneous insulin delivery in diabetic patients. These infusion sets are sold under the Unomedical brand name and are also distributed under other brand names including, but not limited to, MiniMed Mio, MiniMed Mio 30, MiniMed Silhouette, MiniMed Sure-T, MiniMed Quick-Set, MiniMed Mio Advance, Extended Wear Infusion Set, i-port ADVANCE, and Convatec’s inset and contact detach infusion sets for use with compatible third-party insulin pumps. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, the manufacture, packing, storage, or installation of your device are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820. We received your responses dated August 29, 2025, September 29, 2025, and November 14, 2025 concerning our investigator's observations noted during the Remote Regulatory Assessment which were issued to your firm.\u003C\u002Fp>\u003Cp>We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1) Failure to validate processes whose results cannot be fully verified by subsequent inspection and test, as required by 21 CFR 820.75(a). For example, the water leak test method used for in-process and final inspection, complaint investigations, and for tests performed during validations and revalidations has not been validated according to your firm's own procedures, despite being critical for detecting leaks in the insulin infusion sets that could cause insulin under-delivery and diabetic ketoacidosis. Between January 2023 and June 2025, your firm has received more than 5,000 complaints related to leaking of infusion sets, where patients experienced hyperglycemia with diabetic ketoacidosis. The Work Instruction # 3806111, \"Validation of Test Methods (TMV),\" version 9.0, effective February 10, 2025, requires validation of the water leak tester to show that the test \"can consistently and accurately differentiate between the possible test states\"; however, Ms. Victoria Canela, CAPA Manager, stated that the water leak test has not been validated.\u003C\u002Fp>\u003Cp>We have reviewed your responses and conclude that they are not adequate. Your firm opened CAPA-2356512 to address this observation. Your firm provided Document No. M0666.0001, IQ\u002FOQ\u002FPQ Protocol for Validation of Test method for Leak in water Test, version 1.0. Your firm’s updated response states \"This validation has been completed and was submitted as part of our initial response,\" however, the completed validation reports were not provided. The protocol includes \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, the protocol does not describe how appropriate statistical methods for data collection and analysis are used nor define the criteria for revalidation. Your firm should revise your protocol to include \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The revised protocol should be provided for review. When available, your firm should also provide the completed validation reports. Your firm also plans to update the Test Method Validation procedure to add test method validation for all test methods and equipment used in product release, complaint investigations, and validation\u002Frevalidation activities by October 31, 2025. The revised procedure should be provided for review.\u003C\u002Fp>\u003Cp>Finally, your firm plans to conduct a systematic review of all inspection and test equipment used for product release, complaint investigations, and validation\u002Frevalidation activities to identify any other unvalidated processes or equipment and remediate as needed by December 31, 2025. Your firm should ensure your review includes all manufacturing processes, including test methods, to ensure that any process which cannot be fully verified is validated. Your firm should provide the results of your systematic review, identifying the processes and test methods assessed and their validation status. If additional validations are needed your firm should provide a copy of the validation protocols, and if available, final reports.\u003C\u002Fp>\u003Cp>2) Failure to adequately review and investigate complaints involving the possible failure of a device to meet any of its specifications, as required by 21 CFR 820.198(c). For example:\u003C\u002Fp>\u003Cp>a. Your firm's complaint handling procedure, Document 3709030, Complaint handling, versions 12 - 19, effective July 22, 2020 – December 18, 2024 (current) allowed the closure of over 41,000 \"Type 1\" complaints, received between June 2023 and June 2025, without investigation, because lot numbers were missing. These uninvestigated complaints included allegations of leakage, loss of physical integrity, adhesive failures, infections, and death (Complaint 2204208).\u003C\u002Fp>\u003Cp>b. In Complaint 2204208, a patient died with a blood glucose of 1.1. The customer provided the pump serial numbers, transmitter numbers, and material numbers for the reservoir and sensor, however your firm did not investigate because no lot number was provided and no attempt to collect the lot number was documented. The customer agreed to return product, but no effort to obtain the device was documented.\u003C\u002Fp>\u003Cp>We have reviewed your responses and conclude that they are not adequate. Your firm initiated CAPA-2356421 to address this observation. While your firm acknowledges procedural deficiencies and has initiated some corrective actions including reopening complaints 2204208, 1997347, and 2051281, and conducting vigilance training (Document: Infusion Care Complaint Vigilance Awareness Refresher TrainingAttendance25SEP2025.pdf), the corrective actions are still pending. But your firm has not included a plan to address devices which do not conform to specifications which have already been distributed. Specifically, your firm’s plans do not include assessing the risk of distributed products and plans to notify or correct those distributed products which may include any user notifications, corrections, or removals of product already distributed that may be necessary to prevent a risk to health.\u003C\u002Fp>\u003Cp>We acknowledge that in your November 14, 2025 response your firm submitted revised complaint handling procedures and work instructions, however, your firm has not yet provided evidence of implementation of these corrective actions and your firm also plans to conduct a retrospective review of using its revised procedures on complaint data involving leakage, loss of physical integrity, adhesive failure, and infection, and those coded as “cannot be determined” or “no malfunction” received since June 1, 2023, and remediate as needed, by March 2026.It is unclear if this retrospective review will include all complaints involving the possible failure of the device, labeling, or packaging to meet any of its specifications. Your firm should provide a justification for the sample size selected for the retrospective review. Your firm should provide the results of the retrospective review.\u003C\u002Fp>\u003Cp>Your firm also plans to conduct a retrospective trend analysis to identify trends for each reported complaint issue by May 2026. The results of this review should be provided. Furthermore, your firm plans to conduct a retrospective review of complaints involving serious injury and\u002For death and remediate as needed by January 2026. Your firm also plans to conduct additional training regarding product specific information, complaint handling by May 2026. Your firm also plans to implement procedures to regularly audit complaint and “non-complaint” records by February 2026. The procedure and evidence of retraining should be provided for review.\u003C\u002Fp>\u003Cp>3) Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). For example:\u003C\u002Fp>\u003Cp>a. CAPA 1627223 was initiated on February 23, 2023 to address a trend in complaints received for leaking Inset I and Inset II infusion set products. The investigation concluded that the root cause was \u003Cstrong>(b)(4)\u003C\u002Fstrong>, specifically involving \u003Cstrong>(b)(4)\u003C\u002Fstrong> (affecting all manufacturing lines). Corrective actions were implemented (including \u003Cstrong>(b)(4)\u003C\u002Fstrong>) and the CAPA was closed as effective on March 14, 2025 based on a review of complaints received from 2023 and 2024 related to leaks; however, the effectiveness review was only based on a one month search of complaints and, as indicated in item two above, your firm excluded the 41,000 uninvestigated Type 1 complaints in its verification. Furthermore, the verification of effectiveness did not take into consideration whether leak failures were identified through the nonconformance process to ensure the investigation scope and root causes were adequate. Specifically, while CAPA 1627223 was in progress (Feb 2023 - Mar 2025), your firm continued to document the following seven nonconformance reports related to leak failures on Inset I and II products:\u003C\u002Fp>\u003Cdiv>\u003Ctable>\u003Cthead>\u003Ctr>\u003Cth>Nonconformance Number\u003C\u002Fth>\u003Cth>Date Initiated\u003C\u002Fth>\u003Cth>Part Affected\u003C\u002Fth>\u003Cth>Description\u003C\u002Fth>\u003C\u002Ftr>\u003C\u002Fthead>\u003Ctbody>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Inset: Leakage in water test Failure\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Inset: Leak failure on \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Leak on membrane in \u003Cstrong>(b)(4) \u003C\u002Fstrong>product \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Leakage in water test failure on batch \u003Cstrong>(b)(4) \u003C\u002Fstrong>Product\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Failure in leak test test in water \u003Cstrong>(b)(4) \u003C\u002Fstrong>Product\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Failure on the leak test in water.\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Failure on the leak test in water.\u003C\u002Ftd>\u003C\u002Ftr>\u003C\u002Ftbody>\u003C\u002Ftable>\u003C\u002Fdiv>\u003Cp>b. Between December 12, 2022, and October 12, 2023, your firm received 210 complaints reporting the Varisoft infusion set tubing detached from the connector resulting in a high blood glucose level, including 86 with reported harm of hyperglycemia. However, your firm determined a CAPA was not needed even though complaints, such as 1593110 and 1619522 were categorized as severity 5 (death or life-threatening harm which requires professional medical intervention) until August 2023 (CAPA 1723998) following a supplier corrective action report due to complaints that Varisoft infusion sets have easily detached from the connector and\u002For patient line separation. This led to a Class I Recall (FDA RES 93269) initiated on October 11, 2023, more than 11 months after your firm became aware of the product defect. CAPA 1723998 concluded that the product defect was caused by a defective manufacturing machine, corrective actions were implemented, and the CAPA was closed as effective on May 5, 2025, stating “It was found 4 complaints received after the corrective action however after quality analysis on retention samples the failure was not confirmed. Therefore, it can be concluded that the CAPA was effective.” However, review of complaint data revealed approximately 180 complaints were received during the same period used for verification of effectiveness (April 2023 – August 2024), that reported Varisoft infusion set tubing detaching from the connector, including approximately 80 complaints reporting hyperglycemia. These complaints were not included in the verification check because, as indicated in item two above, your firm’s complaint handling process inadequately categorizes and investigates complaints alleging failure of the device.&nbsp;\u003C\u002Fp>\u003Cp>c. CAPA 2010953 was initiated on February 7, 2025, to address a trend of increasing complaints related to over 3,000 complaints of leaking of Extended Wear Infusion Sets (EWIS). The root cause was found to be that your firm did not conduct \u003Cstrong>(b)(4)\u003C\u002Fstrong> verification for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> requirements to ensure the infusion set “stays on the patient for a usage time according to intended use after insertion”. The investigation also revealed that “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”. The CAPA explains there is “\u003Cstrong>(b)(4)\u003C\u002Fstrong>…It is not clear which \u003Cstrong>(b)(4)\u003C\u002Fstrong>”. However, your firm failed to identify any corrective actions to address these device design deficiencies, and the only proposed corrective action is to update the \u003Cstrong>(b)(4)\u003C\u002Fstrong>”. Additionally, CAPA 2010953 was limited to the EWIS products; however, your firm identified that all other product families also do not have \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Furthermore, your firm’s Design Risk Assessment for the EWIS products, Document 3A02087 indicates that potential harm to patients \u003Cstrong>(b)(4)\u003C\u002Fstrong> as 5 (Life threatening or may result in death or disability of patient); however, your firm did not evaluate the potential impact to patients from defective products in the field.\u003C\u002Fp>\u003Cp>d. CAPA 1832980 was initiated on February 21, 2024, to address complaint handling process deficiencies including miscategorized and incorrectly coded complaints. Corrective actions, including remediating complaint records were initiated in April 2024. Complaint numbers 1997347 and 2051281 which were received based on reports of “leaking at the site.” The records document that they had been remediated as part of CAPA 1832980; however, the complaints remain incorrectly coded as: Reported Complaint Issue = “Cannot be determined” and Malfunction Code = “No malfunction based on complaint information”.\u003C\u002Fp>\u003Cp>e. CAPA 1668046 documented that the Inset Guard Ramp-Up product family failed to meet design requirements, including Product Requirement 110.14 (\"\u003Cstrong>(b)(4)\u003C\u002Fstrong>\"), yet your firm closed this CAPA as effective in April 2025 after implementing a \"new\" test method. However, complaint data shows your firm continued to receive approximately 5,000 complaints reporting leakage of Inset Guard Ramp-Up products through June 2025, including reportable malfunctions and serious injuries, indicating that the design verification testing remains inadequate.\u003C\u002Fp>\u003Cp>We have reviewed your firm’s responses and conclude that they are not adequate. Your firm initiated CAPA-2356496 to address this observation. While your firm acknowledges CAPA deficiencies and has initiated some corrective actions including establishing \u003Cstrong>(b)(4)\u003C\u002Fstrong> starting August 27, 2025 (Documents: Meeting Minutes 27 Aug 2025, 10 Sep 2025, 24 Sep 2025), \u003Cstrong>(b)(4)\u003C\u002Fstrong> SOP 3702002 (Corrective and Preventive Action) and related procedures, the corrective actions are still pending. But your firm has not included a plan to address devices which do not conform to specifications which have already been distributed. Specifically, your firm's plans do not include assessing the risk of distributed products from the inadequately investigated CAPAs and any corrections or removals of product already distributed that may be necessary to prevent a risk to health.\u003C\u002Fp>\u003Cp>Your firm plans to complete reassessment of CAPAs 1627223, 2152419, and 2010953 by December 2025, with CAPA 2010953 sent back to investigation on September 22, 2025. Your firm should submit the completed CAPA investigations with verified root causes and objective evidence of effective corrective actions for review.\u003C\u002Fp>\u003Cp>Your firm also plans to conduct a retrospective review of product-related CAPAs closed since June 1, 2023, to ensure adequate verification of effectiveness and reopen as required by March 2026. However, it is unclear if this retrospective review will include assessment of distributed products that may require field action. Your firm should provide a justification for the scope and timeline of the retrospective CAPA review. Your firm should provide the results of the retrospective review.\u003C\u002Fp>\u003Cp>Your firm also plans to \u003Cstrong>(b)(4)\u003C\u002Fstrong> by March 2026. The results of \u003Cstrong>(b)(4)\u003C\u002Fstrong> should be provided. Furthermore, your firm plans to implement \u003Cstrong>(b)(4)\u003C\u002Fstrong> to monitor CAPA progress by October 2025. Your firm also plans to establish a \u003Cstrong>(b)(4)\u003C\u002Fstrong> by November 2025 and \u003Cstrong>(b)(4)\u003C\u002Fstrong> by December 2025. The revised procedures should be provided for review.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Medical Device Reporting (MDR) Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>1. Failure to report the information required by § 803.52 in accordance with the requirements of § 803.12(a), no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1). For example, the information included for Complaint 1997347 reasonably suggests that four of your firm’s AutoSoft XC infusion sets malfunctioned (i.e. device leakage) during use, resulting in elevated blood glucose readings (hyperglycemia) that required the administration of a corrective bolus via the pump. We believe this medical intervention was necessary to prevent permanent impairment of a body function or permanent damage to a body structure. Therefore, each of these four events meets the definition of a reportable serious injury under 21 CFR 803.3. Your firm became aware of these events on September 4, 2024, but failed to submit the corresponding MDR for each of the four reportable serious injury events.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response dated August 29, 2025, and conclude that it is not adequate. In the response, your firm acknowledged the observations and stated that they have initiated a comprehensive plan to address each of the observations. However, your firm did not provide a specific plan describing how the issue will be addressed, nor did they provide a timeline for completion.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response dated September 29, 2025, cannot be determined at this time. The response states that your firm plans to revise its complaint handling and reporting process to address the issue, complete staff training, and will conduct a retrospective review of complaints and submit any newly identified MDRs as appropriate. However, your firm has not provided documentation or evidence to demonstrate that these systemic corrective actions have been fully implemented, including completion of the retrospective review, as these activities are still ongoing.\u003C\u002Fp>\u003Cp>We acknowledge that your firm’s response dated November 14, 2025 included revised complaint handling and reporting procedures and work instructions, however, your firm has not provided evidence of implementation of these new procedures such as training and has not provided the results.\u003C\u002Fp>\u003Cp>2. Failure to report the information required by § 803.52 in accordance with the requirements of §803.12(a), no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets has malfunctioned and this device or a similar device that your firm markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2). For example, the information for Complaint 2051281 reasonably suggests that two of your firm’s AutoSoft XC infusion sets malfunctioned (i.e. device leakage) during use. The serious injury MDR 3003442380-2024-05425, resulting from the same malfunction for the same device, has in the past caused or contributed to a serious injury, thereby establishing precedent that the malfunction would be likely to cause or contribute to a death or serious injury if it were to recur. There is no information included for the complaint that justifies that the referenced malfunction would not be likely to cause or contribute to a death or serious injury. Therefore, the information included for the referenced event represents a reportable malfunction under 21 CFR 803.3. Your firm became aware of these events on October 29, 2024, but failed to submit the corresponding MDR for each of the two reportable malfunction events.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response dated August 29, 2025, and conclude that it is not adequate. In the response, your firm acknowledged the observations and stated that they have initiated a comprehensive plan to address each of the observations. However, your firm did not provide a specific plan describing how the issue will be addressed, nor did they provide a timeline for completion.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response dated September 29, 2025, cannot be determined at this time. The response states that your firm plans to revise its complaint handling and reporting process to address the issue, complete staff training, and will conduct a retrospective review of complaints and submit any newly identified MDRs as appropriate. However, your firm has not provided documentation or evidence to demonstrate that these systemic corrective actions have been fully implemented, including completion of the retrospective review, as these activities are still ongoing.\u003C\u002Fp>\u003Cp>We acknowledge that your firm’s response dated November 14, 2025 included revised complaint handling and reporting procedures and work instructions, however, your firm has not provided evidence of implementation of these new procedures such as training and has not provided the results\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these or similar violations from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrective actions will occur over time, provide a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide English translations of any documentation that is not in English to facilitate our review. We will notify you regarding the adequacy of your firm's responses and we may inspect your facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm's response should be sent via email CDRHEnforcement@fda.hhs.gov. Please include in the subject line: \"CMS Case #719428\" when replying. If you have any questions about the contents of this letter, please contact Ghazaleh Esmaili at Ghazaleh.esmailit@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the observations communicated at the conclusion of the Remote Regulatory Assessment may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to correct them and bring your devices into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Courtney H. Lias, Ph.D.\u003Cbr>Director\u003Cbr>OHT7: Office of In Vitro Diagnostic Devices\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC:\u003Cbr>Courtney Smith\u003Cbr>U.S. Agent\u003Cbr>Courtney.smith@convatec.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nDaihanna Peña\n\nRecipient Title\n\nSenior Director, Plant Operations\n\nUnomedical Device S.A. de C.V.\n\nParque Ind. Del Norte., Ave.\n\nFormento Ind. Lote 9, Sec. 3\n\nReynosa, Tamps.\n\nMexico\n\n(b)(6)@convatec.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS #719428\nJanuary 8, 2026\nDear Ms. Peña:\nDuring a Remote Regulatory Assessment of your firm located in Reynosa, Tamaulipas, Mexico from July 23, 2025 through August 8, 2025, an investigator from the United States Food and Drug Administration (FDA), reviewed the records you submitted in response to our May 22 and June 6, 2025, requests for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, determined that your firm manufactures insulin infusion sets for subcutaneous insulin delivery in diabetic patients. These infusion sets are sold under the Unomedical brand name and are also distributed under other brand names including, but not limited to, MiniMed Mio, MiniMed Mio 30, MiniMed Silhouette, MiniMed Sure-T, MiniMed Quick-Set, MiniMed Mio Advance, Extended Wear Infusion Set, i-port ADVANCE, and Convatec’s inset and contact detach infusion sets for use with compatible third-party insulin pumps. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\nQuality System Regulation Violations\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, the manufacture, packing, storage, or installation of your device are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received your responses dated August 29, 2025, September 29, 2025, and November 14, 2025 concerning our investigator's observations noted during the Remote Regulatory Assessment which were issued to your firm.\nWe address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1) Failure to validate processes whose results cannot be fully verified by subsequent inspection and test, as required by 21 CFR 820.75(a). For example, the water leak test method used for in-process and final inspection, complaint investigations, and for tests performed during validations and revalidations has not been validated according to your firm's own procedures, despite being critical for detecting leaks in the insulin infusion sets that could cause insulin under-delivery and diabetic ketoacidosis. Between January 2023 and June 2025, your firm has received more than 5,000 complaints related to leaking of infusion sets, where patients experienced hyperglycemia with diabetic ketoacidosis. The Work Instruction # 3806111, \"Validation of Test Methods (TMV),\" version 9.0, effective February 10, 2025, requires validation of the water leak tester to show that the test \"can consistently and accurately differentiate between the possible test states\"; however, Ms. Victoria Canela, CAPA Manager, stated that the water leak test has not been validated.\nWe have reviewed your responses and conclude that they are not adequate. Your firm opened CAPA-2356512 to address this observation. Your firm provided Document No. M0666.0001, IQ\u002FOQ\u002FPQ Protocol for Validation of Test method for Leak in water Test, version 1.0. Your firm’s updated response states \"This validation has been completed and was submitted as part of our initial response,\" however, the completed validation reports were not provided. The protocol includes (b)(4). However, the protocol does not describe how appropriate statistical methods for data collection and analysis are used nor define the criteria for revalidation. Your firm should revise your protocol to include (b)(4). The revised protocol should be provided for review. When available, your firm should also provide the completed validation reports. Your firm also plans to update the Test Method Validation procedure to add test method validation for all test methods and equipment used in product release, complaint investigations, and validation\u002Frevalidation activities by October 31, 2025. The revised procedure should be provided for review.\nFinally, your firm plans to conduct a systematic review of all inspection and test equipment used for product release, complaint investigations, and validation\u002Frevalidation activities to identify any other unvalidated processes or equipment and remediate as needed by December 31, 2025. Your firm should ensure your review includes all manufacturing processes, including test methods, to ensure that any process which cannot be fully verified is validated. Your firm should provide the results of your systematic review, identifying the processes and test methods assessed and their validation status. If additional validations are needed your firm should provide a copy of the validation protocols, and if available, final reports.\n2) Failure to adequately review and investigate complaints involving the possible failure of a device to meet any of its specifications, as required by 21 CFR 820.198(c). For example:\na. Your firm's complaint handling procedure, Document 3709030, Complaint handling, versions 12 - 19, effective July 22, 2020 – December 18, 2024 (current) allowed the closure of over 41,000 \"Type 1\" complaints, received between June 2023 and June 2025, without investigation, because lot numbers were missing. These uninvestigated complaints included allegations of leakage, loss of physical integrity, adhesive failures, infections, and death (Complaint 2204208).\nb. In Complaint 2204208, a patient died with a blood glucose of 1.1. The customer provided the pump serial numbers, transmitter numbers, and material numbers for the reservoir and sensor, however your firm did not investigate because no lot number was provided and no attempt to collect the lot number was documented. The customer agreed to return product, but no effort to obtain the device was documented.\nWe have reviewed your responses and conclude that they are not adequate. Your firm initiated CAPA-2356421 to address this observation. While your firm acknowledges procedural deficiencies and has initiated some corrective actions including reopening complaints 2204208, 1997347, and 2051281, and conducting vigilance training (Document: Infusion Care Complaint Vigilance Awareness Refresher TrainingAttendance25SEP2025.pdf), the corrective actions are still pending. But your firm has not included a plan to address devices which do not conform to specifications which have already been distributed. Specifically, your firm’s plans do not include assessing the risk of distributed products and plans to notify or correct those distributed products which may include any user notifications, corrections, or removals of product already distributed that may be necessary to prevent a risk to health.\nWe acknowledge that in your November 14, 2025 response your firm submitted revised complaint handling procedures and work instructions, however, your firm has not yet provided evidence of implementation of these corrective actions and your firm also plans to conduct a retrospective review of using its revised procedures on complaint data involving leakage, loss of physical integrity, adhesive failure, and infection, and those coded as “cannot be determined” or “no malfunction” received since June 1, 2023, and remediate as needed, by March 2026.It is unclear if this retrospective review will include all complaints involving the possible failure of the device, labeling, or packaging to meet any of its specifications. Your firm should provide a justification for the sample size selected for the retrospective review. Your firm should provide the results of the retrospective review.\nYour firm also plans to conduct a retrospective trend analysis to identify trends for each reported complaint issue by May 2026. The results of this review should be provided. Furthermore, your firm plans to conduct a retrospective review of complaints involving serious injury and\u002For death and remediate as needed by January 2026. Your firm also plans to conduct additional training regarding product specific information, complaint handling by May 2026. Your firm also plans to implement procedures to regularly audit complaint and “non-complaint” records by February 2026. The procedure and evidence of retraining should be provided for review.\n3) Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). For example:\na. CAPA 1627223 was initiated on February 23, 2023 to address a trend in complaints received for leaking Inset I and Inset II infusion set products. The investigation concluded that the root cause was (b)(4), specifically involving (b)(4) (affecting all manufacturing lines). Corrective actions were implemented (including (b)(4)) and the CAPA was closed as effective on March 14, 2025 based on a review of complaints received from 2023 and 2024 related to leaks; however, the effectiveness review was only based on a one month search of complaints and, as indicated in item two above, your firm excluded the 41,000 uninvestigated Type 1 complaints in its verification. Furthermore, the verification of effectiveness did not take into consideration whether leak failures were identified through the nonconformance process to ensure the investigation scope and root causes were adequate. Specifically, while CAPA 1627223 was in progress (Feb 2023 - Mar 2025), your firm continued to document the following seven nonconformance reports related to leak failures on Inset I and II products:\nNonconformance NumberDate InitiatedPart AffectedDescription\n(b)(4)(b)(4)(b)(4)Inset: Leakage in water test Failure\n(b)(4)(b)(4)(b)(4)Inset: Leak failure on (b)(4)\n(b)(4)(b)(4)(b)(4)Leak on membrane in (b)(4) product (b)(4)\n(b)(4)(b)(4)(b)(4)Leakage in water test failure on batch (b)(4) Product\n(b)(4)(b)(4)(b)(4)Failure in leak test test in water (b)(4) Product\n(b)(4)(b)(4)(b)(4)Failure on the leak test in water.\n(b)(4)(b)(4)(b)(4)Failure on the leak test in water.\n\nb. Between December 12, 2022, and October 12, 2023, your firm received 210 complaints reporting the Varisoft infusion set tubing detached from the connector resulting in a high blood glucose level, including 86 with reported harm of hyperglycemia. However, your firm determined a CAPA was not needed even though complaints, such as 1593110 and 1619522 were categorized as severity 5 (death or life-threatening harm which requires professional medical intervention) until August 2023 (CAPA 1723998) following a supplier corrective action report due to complaints that Varisoft infusion sets have easily detached from the connector and\u002For patient line separation. This led to a Class I Recall (FDA RES 93269) initiated on October 11, 2023, more than 11 months after your firm became aware of the product defect. CAPA 1723998 concluded that the product defect was caused by a defective manufacturing machine, corrective actions were implemented, and the CAPA was closed as effective on May 5, 2025, stating “It was found 4 complaints received after the corrective action however after quality analysis on retention samples the failure was not confirmed. Therefore, it can be concluded that the CAPA was effective.” However, review of complaint data revealed approximately 180 complaints were received during the same period used for verification of effectiveness (April 2023 – August 2024), that reported Varisoft infusion set tubing detaching from the connector, including approximately 80 complaints reporting hyperglycemia. These complaints were not included in the verification check because, as indicated in item two above, your firm’s complaint handling process inadequately categorizes and investigates complaints alleging failure of the device.\nc. CAPA 2010953 was initiated on February 7, 2025, to address a trend of increasing complaints related to over 3,000 complaints of leaking of Extended Wear Infusion Sets (EWIS). The root cause was found to be that your firm did not conduct (b)(4) verification for the (b)(4) requirements to ensure the infusion set “stays on the patient for a usage time according to intended use after insertion”. The investigation also revealed that “(b)(4)”. The CAPA explains there is “(b)(4)…It is not clear which (b)(4)”. However, your firm failed to identify any corrective actions to address these device design deficiencies, and the only proposed corrective action is to update the (b)(4)”. Additionally, CAPA 2010953 was limited to the EWIS products; however, your firm identified that all other product families also do not have (b)(4). Furthermore, your firm’s Design Risk Assessment for the EWIS products, Document 3A02087 indicates that potential harm to patients (b)(4) as 5 (Life threatening or may result in death or disability of patient); however, your firm did not evaluate the potential impact to patients from defective products in the field.\nd. CAPA 1832980 was initiated on February 21, 2024, to address complaint handling process deficiencies including miscategorized and incorrectly coded complaints. Corrective actions, including remediating complaint records were initiated in April 2024. Complaint numbers 1997347 and 2051281 which were received based on reports of “leaking at the site.” The records document that they had been remediated as part of CAPA 1832980; however, the complaints remain incorrectly coded as: Reported Complaint Issue = “Cannot be determined” and Malfunction Code = “No malfunction based on complaint information”.\ne. CAPA 1668046 documented that the Inset Guard Ramp-Up product family failed to meet design requirements, including Product Requirement 110.14 (\"(b)(4)\"), yet your firm closed this CAPA as effective in April 2025 after implementing a \"new\" test method. However, complaint data shows your firm continued to receive approximately 5,000 complaints reporting leakage of Inset Guard Ramp-Up products through June 2025, including reportable malfunctions and serious injuries, indicating that the design verification testing remains inadequate.\nWe have reviewed your firm’s responses and conclude that they are not adequate. Your firm initiated CAPA-2356496 to address this observation. While your firm acknowledges CAPA deficiencies and has initiated some corrective actions including establishing (b)(4) starting August 27, 2025 (Documents: Meeting Minutes 27 Aug 2025, 10 Sep 2025, 24 Sep 2025), (b)(4) SOP 3702002 (Corrective and Preventive Action) and related procedures, the corrective actions are still pending. But your firm has not included a plan to address devices which do not conform to specifications which have already been distributed. Specifically, your firm's plans do not include assessing the risk of distributed products from the inadequately investigated CAPAs and any corrections or removals of product already distributed that may be necessary to prevent a risk to health.\nYour firm plans to complete reassessment of CAPAs 1627223, 2152419, and 2010953 by December 2025, with CAPA 2010953 sent back to investigation on September 22, 2025. Your firm should submit the completed CAPA investigations with verified root causes and objective evidence of effective corrective actions for review.\nYour firm also plans to conduct a retrospective review of product-related CAPAs closed since June 1, 2023, to ensure adequate verification of effectiveness and reopen as required by March 2026. However, it is unclear if this retrospective review will include assessment of distributed products that may require field action. Your firm should provide a justification for the scope and timeline of the retrospective CAPA review. Your firm should provide the results of the retrospective review.\nYour firm also plans to (b)(4) by March 2026. The results of (b)(4) should be provided. Furthermore, your firm plans to implement (b)(4) to monitor CAPA progress by October 2025. Your firm also plans to establish a (b)(4) by November 2025 and (b)(4) by December 2025. The revised procedures should be provided for review.\nMedical Device Reporting (MDR) Violations\n1. Failure to report the information required by § 803.52 in accordance with the requirements of § 803.12(a), no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1). For example, the information included for Complaint 1997347 reasonably suggests that four of your firm’s AutoSoft XC infusion sets malfunctioned (i.e. device leakage) during use, resulting in elevated blood glucose readings (hyperglycemia) that required the administration of a corrective bolus via the pump. We believe this medical intervention was necessary to prevent permanent impairment of a body function or permanent damage to a body structure. Therefore, each of these four events meets the definition of a reportable serious injury under 21 CFR 803.3. Your firm became aware of these events on September 4, 2024, but failed to submit the corresponding MDR for each of the four reportable serious injury events.\nWe reviewed your firm’s response dated August 29, 2025, and conclude that it is not adequate. In the response, your firm acknowledged the observations and stated that they have initiated a comprehensive plan to address each of the observations. However, your firm did not provide a specific plan describing how the issue will be addressed, nor did they provide a timeline for completion.\nThe adequacy of your firm’s response dated September 29, 2025, cannot be determined at this time. The response states that your firm plans to revise its complaint handling and reporting process to address the issue, complete staff training, and will conduct a retrospective review of complaints and submit any newly identified MDRs as appropriate. However, your firm has not provided documentation or evidence to demonstrate that these systemic corrective actions have been fully implemented, including completion of the retrospective review, as these activities are still ongoing.\nWe acknowledge that your firm’s response dated November 14, 2025 included revised complaint handling and reporting procedures and work instructions, however, your firm has not provided evidence of implementation of these new procedures such as training and has not provided the results.\n2. Failure to report the information required by § 803.52 in accordance with the requirements of §803.12(a), no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets has malfunctioned and this device or a similar device that your firm markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2). For example, the information for Complaint 2051281 reasonably suggests that two of your firm’s AutoSoft XC infusion sets malfunctioned (i.e. device leakage) during use. The serious injury MDR 3003442380-2024-05425, resulting from the same malfunction for the same device, has in the past caused or contributed to a serious injury, thereby establishing precedent that the malfunction would be likely to cause or contribute to a death or serious injury if it were to recur. There is no information included for the complaint that justifies that the referenced malfunction would not be likely to cause or contribute to a death or serious injury. Therefore, the information included for the referenced event represents a reportable malfunction under 21 CFR 803.3. Your firm became aware of these events on October 29, 2024, but failed to submit the corresponding MDR for each of the two reportable malfunction events.\nWe reviewed your firm’s response dated August 29, 2025, and conclude that it is not adequate. In the response, your firm acknowledged the observations and stated that they have initiated a comprehensive plan to address each of the observations. However, your firm did not provide a specific plan describing how the issue will be addressed, nor did they provide a timeline for completion.\nThe adequacy of your firm’s response dated September 29, 2025, cannot be determined at this time. The response states that your firm plans to revise its complaint handling and reporting process to address the issue, complete staff training, and will conduct a retrospective review of complaints and submit any newly identified MDRs as appropriate. However, your firm has not provided documentation or evidence to demonstrate that these systemic corrective actions have been fully implemented, including completion of the retrospective review, as these activities are still ongoing.\nWe acknowledge that your firm’s response dated November 14, 2025 included revised complaint handling and reporting procedures and work instructions, however, your firm has not provided evidence of implementation of these new procedures such as training and has not provided the results\nOther federal agencies may take your compliance with the FD&C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\nPlease notify this office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these or similar violations from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrective actions will occur over time, provide a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide English translations of any documentation that is not in English to facilitate our review. We will notify you regarding the adequacy of your firm's responses and we may inspect your facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm's response should be sent via email CDRHEnforcement@fda.hhs.gov. Please include in the subject line: \"CMS Case #719428\" when replying. If you have any questions about the contents of this letter, please contact Ghazaleh Esmaili at Ghazaleh.esmailit@fda.hhs.gov.\nFinally, this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the observations communicated at the conclusion of the Remote Regulatory Assessment may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to correct them and bring your devices into compliance.\nSincerely,\n\u002FS\u002F\nCourtney H. Lias, Ph.D.\nDirector\nOHT7: Office of In Vitro Diagnostic Devices\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC:\nCourtney Smith\nU.S. Agent\nCourtney.smith@convatec.com","Unomedical Device S.A. de C.V.","unomedical-device-sa-de-cv-719428-01082026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Funomedical-device-sa-de-cv-719428-01082026","2026-10-26T08:10:17.962879+00:00","2026-02-03","719428","Medical Devices","Daihanna Peña","2026-08-19T07:16:06.283+00:00","VIA Electronic Mail","2026-01-08",{"id":117,"raw":118,"subject":122,"body_html":123,"body_text":124,"firm_name":125,"letter_id":126,"created_at":106,"fei_number":20,"letter_url":127,"updated_at":128,"action_type":23,"case_status":24,"posted_date":129,"marcs_cms_no":130,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":20,"body_fetched_at":131,"delivery_method":132,"recipient_title":20,"reference_number":20,"action_taken_date":133,"medical_device_id":20,"response_letter_date":20},472,[119,120,121,11,122,13,13,13],"\u003Ctime datetime=\"2025-11-18T05:00:00Z\">11\u002F18\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-11-13T05:00:00Z\">11\u002F13\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedical-mega-717840-11132025\">Medical Mega\u003C\u002Fa>","Nonprescription\u002FOTC","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Medical Mega\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>208 Fairmont Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Jersey City\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07306\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Sales@medicalmega.com\"> Sales@medicalmega.com  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>November 13, 2025\u003C\u002Fp>\u003Cp>RE: 717840\u003C\u002Fp>\u003Cp>Medical Mega:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the internet address https:\u002F\u002Fwww.medicalmega.com. The FDA has observed that your website offers the following triclosan-containing consumer and health care antiseptic nonprescription drug products: “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 800 mL,” “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 1 Gallon,” and “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 1000 mL” (hereinafter “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan”) for sale in United States. Based on our review, these products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 331(d). In addition, these products are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under sections 301 (d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>“Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are “drugs” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Examples from the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” product labeling, including your website, https:\u002F\u002Fwww.medicalmega.com, that provide evidence of the intended use (as defined in 21 CFR 201.128) of the products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>“Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan”\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“Anti-microbial…Kills bacteria on contact…” [from your https:\u002F\u002Fmedicalmega.com\u002FAmeriWash-Antimicrobial-Lotion-Soap-with-Triclosan-1000-mL product page]\u003C\u002Fp>\u003Cp>Based on the above labeling evidence, the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are intended for use as triclosan-containing consumer and health care antiseptic nonprescription drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling; and in general, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for the drug products identified above.\u003C\u002Fp>\u003Cp>With respect to triclosan-containing consumer and health care antiseptic nonprescription drug products, such as the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan,” such products are subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, these products fall under section 505G(a)(5) of the FD&amp;C Act, 21 U.S.C. 355h(a)(5), because FDA has determined that topical consumer and health care antiseptic nonprescription drug products formulated with triclosan as an active ingredient are not GRASE under a final determination issued under 21 CFR part 330.1\u003C\u002Fp>\u003Cp>Therefore, these products are new drugs within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). No FDA-approved application pursuant to section 505 of the FD&amp;C Act is in effect for these drug products. Accordingly, these products are unapproved new drugs marketed in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\u003Cp>In addition, the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov, please include your firm name and the unique identifier “717840” in the subject line of the email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>_________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> On September 6, 2017, FDA issued a final rule establishing that certain ingredients for OTC topical consumer antiseptic wash nonprescription drug products, including triclosan, are not generally recognized as safe and effective (81 FR 61106). FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(27)(iii). On December 20, 2018, FDA issued a final rule establishing that certain ingredients for OTC health care antiseptic hand wash nonprescription drug products, including triclosan, are not generally recognized as safe and effective (82 FR 60474). FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(27)(vi). Under section 505G(k)(2)(A) of the FD&amp;C Act, the non-monograph conditions in 21 CFR 310.545 in effect on the day before the date of enactment of the CARES Act (i.e., March 26, 2020) were deemed to be a final administrative order. The final administrative order is entitled “Non-Monograph Conditions NM900: Drug Products Containing Certain Active Ingredients Offered Over-the-Counter for Certain Uses” (See Order ID OTC 000007, available at OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nMedical Mega\n\n208 Fairmont Ave\n\nJersey City, NJ 07306\n\nUnited States\n\nSales@medicalmega.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nNovember 13, 2025\nRE: 717840\nMedical Mega:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the internet address https:\u002F\u002Fwww.medicalmega.com. The FDA has observed that your website offers the following triclosan-containing consumer and health care antiseptic nonprescription drug products: “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 800 mL,” “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 1 Gallon,” and “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 1000 mL” (hereinafter “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan”) for sale in United States. Based on our review, these products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d). In addition, these products are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under sections 301 (d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\nUnapproved New Drug and Misbranded Drug Violations\n“Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are “drugs” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\nExamples from the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” product labeling, including your website, https:\u002F\u002Fwww.medicalmega.com, that provide evidence of the intended use (as defined in 21 CFR 201.128) of the products as drugs include, but may not be limited to, the following:\n“Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan”\n“Anti-microbial…Kills bacteria on contact…” [from your https:\u002F\u002Fmedicalmega.com\u002FAmeriWash-Antimicrobial-Lotion-Soap-with-Triclosan-1000-mL product page]\nBased on the above labeling evidence, the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are intended for use as triclosan-containing consumer and health care antiseptic nonprescription drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling; and in general, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for the drug products identified above.\nWith respect to triclosan-containing consumer and health care antiseptic nonprescription drug products, such as the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan,” such products are subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, these products fall under section 505G(a)(5) of the FD&C Act, 21 U.S.C. 355h(a)(5), because FDA has determined that topical consumer and health care antiseptic nonprescription drug products formulated with triclosan as an active ingredient are not GRASE under a final determination issued under 21 CFR part 330.1\nTherefore, these products are new drugs within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p). No FDA-approved application pursuant to section 505 of the FD&C Act is in effect for these drug products. Accordingly, these products are unapproved new drugs marketed in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. 331(d).\nIn addition, the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction.\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov, please include your firm name and the unique identifier “717840” in the subject line of the email.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n_________________\n1 On September 6, 2017, FDA issued a final rule establishing that certain ingredients for OTC topical consumer antiseptic wash nonprescription drug products, including triclosan, are not generally recognized as safe and effective (81 FR 61106). FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(27)(iii). On December 20, 2018, FDA issued a final rule establishing that certain ingredients for OTC health care antiseptic hand wash nonprescription drug products, including triclosan, are not generally recognized as safe and effective (82 FR 60474). FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(27)(vi). Under section 505G(k)(2)(A) of the FD&C Act, the non-monograph conditions in 21 CFR 310.545 in effect on the day before the date of enactment of the CARES Act (i.e., March 26, 2020) were deemed to be a final administrative order. The final administrative order is entitled “Non-Monograph Conditions NM900: Drug Products Containing Certain Active Ingredients Offered Over-the-Counter for Certain Uses” (See Order ID OTC 000007, available at OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F).","Medical Mega","medical-mega-717840-11132025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedical-mega-717840-11132025","2026-10-26T08:09:22.956521+00:00","2025-11-18","717840","2026-08-19T14:27:25.954+00:00","Via Email","2025-11-13",6,{"510k":136,"classification":137,"enforcement":138,"event":139,"event_backfill":140,"pma":141,"warning_letter":142},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]